- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| COMPASS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Mi | Compass Therapeutics to Participate in Upcoming Investor Events | 1 | GlobeNewswire (USA) | ||
| Di | Compass Therapeutics GAAP EPS of -$0.08 | 1 | Seeking Alpha | ||
| Di | Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update | 38 | GlobeNewswire (Europe) | Fully enrolled the Phase 2/3 trial of lead asset CTX-009 (DLL4 and VEGF-A bispecific antibody) in patients with biliary tract cancers (BTC); top-line data readout is on track for the end of the first... ► Artikel lesen | |
| Di | Compass Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| Fr | Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting | 67 | GlobeNewswire (Europe) | New data showed a correlation between the levels of neural cell adhesion molecule (NCAM or CD56) expression and response and disease control in patients treated with CTX-471 monotherapy.Predictive... ► Artikel lesen | |
| 04.10. | Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 03.09. | Compass Therapeutics to Participate in Upcoming Investor Events | 1 | GlobeNewswire (USA) | ||
| 30.08. | Compass Therapeutics files $300M mixed securities shelf | 1 | Seeking Alpha | ||
| 12.08. | Compass Therapeutics GAAP EPS of -$0.10, revenue of $0.85M | 1 | Seeking Alpha | ||
| 12.08. | Compass Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 12.08. | Compass Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.08. | Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference | 1 | GlobeNewswire (USA) | ||
| 17.06. | Compass Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.05. | Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference | 1 | GlobeNewswire (USA) | ||
| 28.05. | Compass Therapeutics names Thomas Schuetz as CEO | 1 | Seeking Alpha | ||
| 28.05. | Compass Therapeutics Announces CEO Transition | 130 | GlobeNewswire (Europe) | BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics... ► Artikel lesen | |
| 28.05. | Compass Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.05. | Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) ... | 2 | GlobeNewswire (USA) | ||
| 09.04. | Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting | 168 | GlobeNewswire (Europe) | Major Histocompatibility Complex Class I (MHC-I) negative tumors are refractory to immune-oncology therapies, including resistance to checkpoint blockers, due to the loss of the fundamental recognition... ► Artikel lesen | |
| 21.03. | Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update | 136 | GlobeNewswire (Europe) | Enrollment in COMPANION-002, the Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), continues to progress well; top-line... ► Artikel lesen |
Seite:
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,350 | +20,54 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,396 | +0,76 % | Defence Therapeutics Inc. begrüßt Dr. Svetlana Selivanova, Expertin für Radiopharmazeutika, im Board of Directors | Vancouver, BC, Kanada, 13. November 2024 / IRW-Press / Defence Therapeutics Inc. ("Defence" oder das
"Unternehmen") (CSE: DTC, OTCQB: DTCFF, FWB: DTC), ein kanadisches biopharmazeutisches Unternehmen... ► Artikel lesen | |
| GINKGO BIOWORKS | 7,950 | -2,45 % | Ginkgo Bioworks Reports Third Quarter 2024 Financial Results | Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions
Ginkgo... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,280 | -0,41 % | Recursion Pharmaceuticals: Recursion and Exscientia Shareholders Approve the Proposed Combination | Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated closeSalt Lake City USA, Oxford UK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) and Exscientia plc (Nasdaq:... ► Artikel lesen | |
| BEAM THERAPEUTICS | 27,230 | -0,95 % | Beam Therapeutics Inc. Q3 Loss Misses Estimates | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) reported Loss for third quarter that missed the Street estimates.The company's earnings came in at -$96.668 million, or -$1.17 per share.... ► Artikel lesen | |
| ONCOLYTICS BIOTECH | 0,995 | 0,00 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Third Quarter 2024 Financial Results and Operational Highlights | BRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms pelareorep + paclitaxel combination should be evaluated in a registrational study
Upcoming... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 19,280 | 0,00 % | Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious... ► Artikel lesen | |
| ASSERTIO | 0,863 | +0,52 % | Assertio Holdings, Inc.: Assertio Reports Third Quarter 2024 Financial Results | Third Quarter Total Net Product Sales of $28.7 Million Rolvedon Net Product Sales of $15.0 Million Cash and Short-Term Investments of $88.6 Million LAKE FOREST, Ill., Nov. 11, 2024 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 6,700 | +1,67 % | SIGA TECHNOLOGIES INC - 10-Q, Quarterly Report | ||
| ADMA BIOLOGICS | 21,070 | -1,86 % | ADMA Biologics-Aktie erreicht Allzeithoch von 21,25 US-Dollar | ||
| VIR BIOTECHNOLOGY | 8,800 | -2,11 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
| MERRIMACK PHARMACEUTICALS | 15,130 | 0,00 % | MERRIMACK PHARMACEUTICALS INC - 15-12G, Securities registration termination | ||
| VERVE THERAPEUTICS | 5,610 | -3,03 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 17,800 | +1,14 % | Travere Therapeutics, Inc.: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement... ► Artikel lesen | |
| ARVINAS | 25,350 | +0,24 % | Arvinas-Chefbuchhalter David Loomis verkauft Aktien im Wert von 10.300 US-Dollar |
COMPASS THERAPEUTICS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,040 (-2,35 %) liegt der Kurs bei 1,660 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu COMPASS THERAPEUTICS INC finden Sie auf Wallstreet Online.
